Internal Medicine

Phase 2 monotherapy arms show lower response, shorter survival, and similar-or-worse toxicity versus phase 3.

Across 130 phase 2 and 52 phase 3 monotherapy arms (6665 vs 18,694 patients), pooled objective response was 7% in phase 2 versus 24% in phase 3. Median PFS and OS were shorter in phase 2 than phase 3 (3.23 vs 5.43 months; 9.46 vs 14.44 months). Drug-related grade 3–4 adverse events occurred in 30% of phase 2 versus 25% of phase 3 arms. Authors conclude phase 2 monotherapy administration generally offers diminished risk–benefit and should be framed as research, not therapeutic care. 1

Run-in phases and single-arm designs can markedly shrink geographic atrophy trial sample sizes.

GA enlargement rates were stable, enabling run-in or single-arm designs to preserve power with fewer participants. For 2‑year trials at 90% power, sample size estimates fell from 156 (standard RCT) to 82, 40, and 26 with 3, 6, and 9‑month run-ins respectively. A 2‑year single-arm trial with a 9‑month run-in required 14 participants versus 26 for a comparable RCT. Findings derive from simulations using GA Minocycline Trial parameters and should guide trial design rather than immediate clinical practice changes. 2

Win ratio use is rising but component discordance can alter conclusions.

The study reviewed 90 WR applications (35 pre-specified, 55 re-analyses), mostly in circulatory system trials. Component-level discordance was common: 36 of 139 components (25.9%) in pre-specified analyses conflicted or were neutral versus the overall WR point estimate. Among 35 studies compared at the conclusion level, 22 had WR conclusions consistent with original trials. Changes in component selection or prioritization largely explained discrepant WR conclusions, so interpret WR results with attention to endpoint hierarchy. 3